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Aim
Evidence-based practice is essential to improving
patient safety and the effectiveness of health care prac-
tices. The impact of therapeutic drug monitoring
(TDM) on patients outcomes must be evaluated
accordingly. Members of the ‘TDM group’ of the
French Society of Pharmacology and Therapeutics
worked together to address the role of TDM for var-
ious drugs. HIV protease inhibitors (PI) and non
nucleoside reverse transcriptase inhibitors (NNRTI)
have been evaluated in this context.
Methods
A systematic review of the literature was done. Pub-
lished studies were analyzed and classified according to
the methodology used: randomized or not, number of
patients, exposition-efficacy and/or toxicity relation-
ship, statistic method, pharmacokinetic parameters
evaluated.
Results
The level of evidence for the TDM of atazanavir, ampre-
navir, lopinavir, indinavir, saquinavir, efavirenz and
nevirapine was evaluated. Several controlled and non-
controlled studies have been performed for these drugs,
reporting pharmacokinetic-pharmacodynamic correla-
tions on treatment efficacy and for some adverse effects,
such as atazanavir and bilirubin elevations or efavirenz
and neurological disorders.
Discussion
The level of evidence of the interest of first generation
PI and NNRTI TDM is recommended, which is in
accordance with the French and European recommenda-
tions for the management of HIV-infected patients.
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